These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

775 related articles for article (PubMed ID: 30413827)

  • 1. Cytokines in clinical cancer immunotherapy.
    Berraondo P; Sanmamed MF; Ochoa MC; Etxeberria I; Aznar MA; Pérez-Gracia JL; Rodríguez-Ruiz ME; Ponz-Sarvise M; Castañón E; Melero I
    Br J Cancer; 2019 Jan; 120(1):6-15. PubMed ID: 30413827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From antibodies to living drugs: Quo vadis cancer immunotherapy?
    Szöőr Á; Szöllősi J; Vereb G
    Biol Futur; 2021 Mar; 72(1):85-99. PubMed ID: 34554498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Checkpoint Inhibitors and Cytokines in Adoptive Cell-Based Cancer Immunotherapy with Genetically Modified T Cells.
    Gershovich PM; Karabelskii AV; Ulitin AB; Ivanov RA
    Biochemistry (Mosc); 2019 Jul; 84(7):695-710. PubMed ID: 31509722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.
    Bell M; Gottschalk S
    Front Immunol; 2021; 12():684642. PubMed ID: 34177932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
    Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
    Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future.
    Zhang Z; Miao L; Ren Z; Tang F; Li Y
    Front Immunol; 2021; 12():718686. PubMed ID: 34386015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navigating CAR-T cells through the solid-tumour microenvironment.
    Hou AJ; Chen LC; Chen YY
    Nat Rev Drug Discov; 2021 Jul; 20(7):531-550. PubMed ID: 33972771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer.
    Chmielewski M; Abken H
    Cancer Immunol Immunother; 2012 Aug; 61(8):1269-77. PubMed ID: 22274776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
    Young PA; Morrison SL; Timmerman JM
    Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
    Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
    Front Immunol; 2021; 12():738456. PubMed ID: 34721401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Th1 cytokine-based immunotherapy for cancer.
    Xu HM
    Hepatobiliary Pancreat Dis Int; 2014 Oct; 13(5):482-94. PubMed ID: 25308358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumor immunotherapy].
    Błoński JZ; Warzocha K
    Postepy Hig Med Dosw; 1994; 48(6):701-28. PubMed ID: 7675731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
    Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
    Front Immunol; 2020; 11():832. PubMed ID: 32457754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.
    Anna F; Bole-Richard E; LeMaoult J; Escande M; Lecomte M; Certoux JM; Souque P; Garnache F; Adotevi O; Langlade-Demoyen P; Loustau M; Caumartin J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.